![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Cytogen Initiates Clinical Development of Proprietary PSMA Antibody
Cytogen Initiates Clinical Development of Proprietary PSMA Antibody
Cytogen, a product-driven biopharmaceutical company, has announced a new clinical development initiative for a targeted oncology product designed to treat prostate and other cancers.
The product candidate uses DOTA-based bifunctional chelant technology to radiolabel Cytogen's proprietary monoclonal antibody to prostate-specific membrane antigen with a therapeutic radionuclide.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct